The Probiotic Effects of the Saccharomyces cerevisiae 28-7 Strain Isolated from Nuruk in a DSS-Induced Colitis Mouse Model
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Probiotics are microorganisms that can benefit host health when ingested in a live state, and lactic acid bacteria are the most common type. Among fungi, Saccharomyces boulardii (SB) is the only strain known to have a probiotic function with beneficial effects on colitis; however, information on other probiotic yeast strains is limited. Therefore, this study aimed to discover yeast strains expressing intestinal anti-inflammatory activities by exhibiting probiotic properties in dextran sodium sulfate (DSS)-induced colitis mice model. Nuruk (Korean traditional fermentation starter) containing various microbial strains was used as a source for yeast strains, and S. cerevisiae 28-7 (SC28-7) strain was selected with in vitro and in vivo characteristics to enable survival in the intestines. After 14 days of pretreatment with the yeast strains, DSS was co-administered for six days to induce colitis in mice. The results revealed that the disease activity index score was lowered by SC28-7 treatment compared to the DSS group, and the colon length and weight/length ratio were recovered in a pattern similar to that of the normal group. SC28-7 administration significantly reduced the secretion of pro-inflammatory cytokines in the serum and modified the mRNA expression of inflammatory cytokines (interleukin-1β, transforming growth factor-β, and interferon-γ) and proteins involved in gut barrier functions (mucin 2, mucin 3, zonula occludens-1, and occludin) in colon tissues. These results indicate that SC28-7 attenuates DSS-induced colon damage and inflammation, supporting its future use as a probiotic yeast for treating and preventing intestinal inflammatory diseases such as inflammatory bowel disease.
Abstract
Probiotics are microorganisms that can benefit host health when ingested in a live state, and lactic acid bacteria are the most common type. Among fungi, Saccharomyces boulardii (SB) is the only strain known to have a probiotic function with beneficial effects on colitis; however, information on other probiotic yeast strains is limited. Therefore, this study aimed to discover yeast strains expressing intestinal anti-inflammatory activities by exhibiting probiotic properties in dextran sodium sulfate (DSS)-induced colitis mice model. Nuruk (Korean traditional fermentation starter) containing various microbial strains was used as a source for yeast strains, and S. cerevisiae 28-7 (SC28-7) strain was selected with in vitro and in vivo characteristics to enable survival in the intestines. After 14 days of pretreatment with the yeast strains, DSS was co-administered for six days to induce colitis in mice. The results revealed that the disease activity index score was lowered by SC28-7 treatment compared to the DSS group, and the colon length and weight/length ratio were recovered in a pattern similar to that of the normal group. SC28-7 administration significantly reduced the secretion of pro-inflammatory cytokines in the serum and modified the mRNA expression of inflammatory cytokines (interleukin-1β, transforming growth factor-β, and interferon-γ) and proteins involved in gut barrier functions (mucin 2, mucin 3, zonula occludens-1, and occludin) in colon tissues. These results indicate that SC28-7 attenuates DSS-induced colon damage and inflammation, supporting its future use as a probiotic yeast for treating and preventing intestinal inflammatory diseases such as inflammatory bowel disease.
참고문헌 (31)
- Ranjha M, "Nutritional and health potential of probiotics : a review", Appl. Sci, 11, pp.11024~ (2021)
- Goktas H, "Comparison of functional characteristics of distinct Saccharomyces boulardii strains isolated from commercial food supplements", Lwt-Food Sci. Technol, 136, pp.110340~ (2021)
- Lara-Hidalgo C, "Yeasts in fermented foods and their probiotic potential", Austin. J. Nutr. Metab, 4, pp.1~8 (2017)
- Lazo-Velez MA, "Application of Saccharomyces cerevisiae var. boulardii in food processing: a review", J. Appl. Microbiol, 125, pp.943~951 (2018)
- Marcella Lobato D. Consoli, "Randomized Clinical Trial", Journal of Parenteral and Enteral Nutrition, 40(8), pp.1114~1121 (2016), Wiley[DOI]
- Stier H, "Influence of Saccharomyces boulardii CNCM I-745 on the gut-associated immune system", Clin. Exp. Gastroenterol, 9, pp.269~279 (2016)
- Zhou BG, "Saccharomyces boulardii as an adjuvant therapy for Helicobacter pylori eradication : a systematic review and meta-analysis with trial sequential analysis", Helicobacter, 24, pp.e12651~ (2019)
- Lee JE, "Alteration of gut microbiota composition by short-term low-dose alcohol intake is restored by fermented rice liquor in mice", Food Res. Int, 128, pp.108800~ (2020)
- 이은정, "전통누룩에서 분리한 Saccharomyces cerevisiae var. Boulardii-03 효모의 Probiotic 특성 연구", 한국식품영양과학회지, 50(12), pp.1392~1398 (2021), 한국식품영양과학회
- 이장은, "Restoration of Traditional Korean Nuruk and Analysis of the Brewing Characteristics", Journal of Microbiology and Biotechnology, 27(5), pp.896~908 (2017), 한국미생물·생명공학회[DOI]
- Julien Gommeaux, "Colitis and Colitis-Associated Cancer Are Exacerbated in Mice Deficient for Tumor Protein 53-Induced Nuclear Protein 1", Molecular and Cellular Biology, 27(6), pp.2215~2228 (2007), Informa UK Limited[DOI]
- Everard A, "Saccharomyces boulardii administration changes gut microbiota and reduces hepatic steatosis, low-grade inflammation, and fat mass in obese and type 2 diabetic db", db mice, 2014, pp.5, 01011~01014
- Jing-Jing Liu, "A mutation in PGM2 causing inefficient galactose metabolism in the probiotic yeast Saccharomyces boulardii", Applied and Environmental Microbiology, 84(10) (2018), American Society for Microbiology[DOI]
- Mitterdorfer G, "Utilization of prebiotic carbohydrates by yeasts of therapeutic relevance", Lett. Appl. Microbiol, 33, pp.251~255 (2001)
- Edwards-Ingram L, "Genotypic and physiological characterization of Saccharomyces boulardii, the probiotic strain of Saccharomyces cerevisiaev", Appl. Environmen. Microbiol, 73, pp.2458~2467 (2007)
- GraffS, "Influence of pH conditions on the viability of Saccharomyces boulardii yeast", J. Gen. Appl. Microbiol, 54, pp.221~227 (2008)
- GraffS, "Influence of pH conditions on the viability of Saccharomyces boulardii yeast", J. Gen. Appl. Microbiol, 54, pp.221~227 (2008)
- Khatri I, "Complete genome sequence and comparative genomics of the probiotic yeast Saccharomyces boulardii", Sci. Rep, 7, pp.371~ (2017)
- Arafa HM, "Prophylactic role of curcumin in dextran sulfate sodium(DSS)-induced ulcerative colitis murine model", Food Chem. Toxicol, 47, pp.1311~1317 (2009)
- Rodriguez-Nogales A, "Intestinal anti-inflammatory effect of the probiotic Saccharomyces boulardii in DSS-induced colitis in mice : Impact on microRNAs expression and gut microbiota composition", J. Nutr. Biochem, 61, pp.129~139 (2018)
- Qi XW, "Expression features of CXCR5 and its ligand, CXCL13 associated with poor prognosis of advanced colorectal cancer", Eur. Rev. Med. Pharmacol. Sci, 18, pp.1916~1924 (2014)
- Zhu ZY, "CXCL13-CXCR5 axis promotes the growth and invasion of colon cancer cells via PI3K", AKT pathway, 2015, pp.400, 287~295
- Cremonesi E, "Gut microbiota modulate T cell trafficking into human colorectal cancer", Gut, 67, pp.1984~1994 (2018)
- Zhao Q, "CXCL13 promotes intestinal tumorigenesis through the activation of epithelial AKT signaling", Cancer Lett, 511, pp.1~14 (2021)
- Alzoghaibi MA, "Neutrophil chemokines GCP-2 and GRO-alpha in patients with inflammatory bowel disease", J. Digest Dis, 9, pp.144~148 (2008)
- Morris KT, "Anti-G-CSF treatment induces protective tumor immunity in mouse colon cancer by promoting NK cell, macrophage and T cell responses", Oncotarget, 6, pp.22338~22347 (2015)
- Meng CY, "TIMP-1 is a novel serum biomarker for the diagnosis of colorectal cancer : a meta-analysis", PLoS One, 13, pp.e0207039~ (2018)
- Sanjabi S, "Anti-inflammatory and pro-inflammatory roles of TGF-β, IL-10, and IL-22in immunity and autoimmunity", Curr. Opin. Pharmacol, 9, pp.447~453 (2009)
- Li G, "Oral pirfenidone protects against fibrosis by inhibiting fibroblast proliferation and TGF-beta signaling in a murine colitis model", Biochem. Pharmacol, 117, pp.57~67 (2016)
- Hahm KB, "Loss of transforming growth factor beta signalling in the intestine contributes to tissue injury in inflammatory bowel disease", Gut, 49, pp.190~198 (2001)
- McFarland LV, "Systematic review and meta-analysis of Saccharomyces boulardii in adult patients", World J. Gastroenterol, 16, pp.2202~2222 (2010)